Nemaura Medical Appoints Industry Veteran Alistair Longmuir as Advisor on Global Product Manufacture Strategy
March 04 2021 - 8:00AM
Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”),
a medical technology company focused on developing and
commercializing non-invasive wearable diagnostic devices and
supporting personalized lifestyle coaching programs, today
announces the appointment of industry stalwart Alistair Longmuir as
an advisor for their global product manufacture strategy.
“Ally’s work in the medical device field make
him a vital addition to the Nemaura team as we build our commercial
manufacturing partnerships. His extensive experience in the
methodologies of R&D, manufacturing and deep industry insight
will help serve to guide us as we continue to improve upon our
current offerings and expand into new areas. We look forward to his
leadership and guidance as we continue to round out our leadership
team,” said Faz Chowdhury, Ph.D., Nemaura’s CEO.
Mr. Longmuir has over 30 Years engineering
experience in the fields of in vitro diagnostics, automotive,
smartcard applications and military systems. Prior to joining the
Nemaura Medical team, Ally was at Johnson & Johnson
(J&J) and Lifescan for a total of 16 years, where he was
Director of R&D with responsibility for the strategic
leadership of LifeScan’s blood glucose monitoring development .
With the divestiture of Lifescan from J&J, during that time,
Ally continued strategic leadership of IVD blood glucose platforms,
shaped the new R&D devices organization delivering high quality
and cost-efficient products, driving product strategy, innovation
and external partnerships.
Through his time at LifeScan, he built a wealth
of specialist knowledge in the full end-to-end development of
medical devices & products demonstrated by the many products he
has launched in North America, LATAM, EMEA, APAC delivering
multi-million-dollar revenue with FDA, CE and other global
certifications. He has a proven track record in the delivery of
connected medical devices, launching multiple products on a global
scale, used by over 20million patients on a daily basis.
Mr. Longmuir has several patents related to
diabetes monitoring and has presented to the U.S. FDA on blood
glucose meter development and manufacturing as part of their
internal auditor teaching program.
He has a BSc (Hons) in Electronics and Software
Engineering earned at the Open University.
“Nemaura has a cutting-edge approach to diabetes
care and has demonstrated that the combination of behavioral
modification and a wearable, disposable device to closely monitor
glucose trends may make a significant difference in the lives of
those with diabetes and pre-diabetes. I’m looking forward to
integrating with the team and helping the company achieve these
goals,” added Mr. Langmuir.
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology
company developing and commercializing non-invasive wearable
diagnostic devices. The Company is currently commercializing
sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb
medical device, is a non-invasive and flexible continuous glucose
monitor (CGM) providing actionable insights derived from real time
glucose measurements and daily glucose trend data, which may help
people with diabetes and pre-diabetes to better manage, reverse,
and prevent the onset of diabetes. Nemaura has submitted a PMA
(Premarket Approval Application) for sugarBEAT® to the U.S. FDA.
proBEAT™ combines non-invasive glucose data processed using
artificial intelligence and a digital healthcare subscription
service, launched in the U.S. as part of its BEATdiabetes
program.
The Company sits at the intersection of the
global Type 2 diabetes market that is expected to reach nearly $59
billion by 2025, the $50+ billion pre-diabetic market, and the
wearable health-tech sector for weight loss and wellness
applications that is estimated to reach $60 billion by 2023.
For more information, please visit www.NemauraMedical.com.
Cautionary Statement Regarding Forward-Looking
Statements:
The statements in this press release that are
not historical facts may constitute forward-looking statements that
are based on current expectations and are subject to risks and
uncertainties that could cause actual future results to differ
materially from those expressed or implied by such statements.
Those risks and uncertainties include, but are not limited to, the
launch of proBEAT™ in the US, risks related to regulatory status
and the failure of future development and preliminary marketing
efforts, Nemaura’s ability to secure additional commercial
partnering arrangements, risks and uncertainties relating to
Nemaura and its partners’ ability to develop, market and sell
proBEAT™, the availability of substantial additional equity or debt
capital to support its research, development and product
commercialization activities, and the success of its research,
development, regulatory approval, marketing and distribution plans
and strategies, including those plans and strategies related to
both proBEAT™ digital health, and sugarBEAT®. There can be no
assurance that the company will be able to reach a part of or any
of the global market for CGM with its products/services. The FDA
reserves the right to re-evaluate their decision that proBEAT™
qualifies as a general wellness product should it become aware of
any issues such as skin irritation or other adverse events from the
device, as well as any misuse impacting patient safety, and any
other reason as the FDA may see fit at its discretion to determine
the product does not fit the definition of a general wellness
product. These and other risks and uncertainties are identified and
described in more detail in Nemaura’s filings with the United
States Securities and Exchange Commission, including, without
limitation, its Annual Report on Form 10-K for the most recently
completed fiscal year, its Quarterly Reports on Form 10-Q, and its
Current Reports on Form 8-K. Nemaura undertakes no obligation to
publicly update or revise any forward-looking statements.
Contact:
Jules Abraham CORE IR 917-885-7378 julesa@coreir.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2023 to Jul 2024